Skip to main content

Table 2 Virus neutralization properties of sera with distinct neutralization activities.

From: Chimeric HP-PRRSV2 containing an ORF2-6 consensus sequence induces antibodies with broadly neutralizing activity and confers cross protection against virulent NADC30-like isolate

PRRSV subgroups Representative isolates Mock inoculation TJM-F92 inoculation rJS-ORF2-6-CON inoculation
Pig 3 Pig 6 Pig 12
JXA1-like HP-PRRSV2 JSTZ1712-12
(MK906026)
(99/92)a
< 8b 64 32
JXA1-R
(MT163314)
(99/91)
< 8 32 16
CH-1a-like PRRSV2 SD1612-1
(MN119304)
(96/93)
< 8 < 8 32
CH-1R
(EU807840)
(96/93)
< 8 < 8 16
VR-2332-like PRRSV2 JSYC20-05-1
(MT746146)
(92/94)
< 8 < 8 16
R98
(DQ355796)
(92/94)
< 8 < 8 16
NADC30-like PRRSV2 SD17-36
(MH121061)
(86/90)
< 8 < 8 8
SD17-38
(MH068878)
(85/90)
< 8 < 8 16
NADC34-like PRRSV2 Anheal-1
(MH370474)
(86/90)
< 8 < 8 8
PRRSV1 HLJB1
(KT224385)
(61/65)
< 8 < 8 8
  1. aThe numbers indicate the nucleotide identities between ORF2-6 sequences of TJM-F92 vaccine/chimeric virus (rJS-ORF2-6-CON) and ORF2-6 from representative PRRSV isolates, respectively.
  2. bThe neutralization titer shows an inverse of the highest serum dilution with virus neutralization activity. Titer < 8 indicates no detectable virus neutralization activity.